{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
lactic acid
to a specific field?
Status:
US Previously Marketed
Source:
LORFAN by ROCHE
(1956)
Source URL:
First approved in 1956
Source:
LORFAN by ROCHE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Levallorphan (brand name Lorfan), is an opiate antagonist of morphine family. Levallorphan was formerly used in general anesthesia, mainly to reverse the respiratory depression produced by opioid analgesics and barbiturates used for induction of surgical anaesthesia whilst maintaining a degree of analgesia. Levallorphan was also used in combination with opioid analgesics to reduce their side effects, mainly in obstetrics. The combination of levallorphan with pethidine was used so frequently, a standardized formulation was made available, known as Pethilorfan, by Roche Products Ltd in later 1950s. Is known to be used for narcotic overdose. Levallorphan is similar to naloxone but differs from naloxone in that it also possesses some agonist properties. It acts as an antagonist and partial agonist of the mu opioid receptor (MOR). Levallorphan can produce severe mental reactions at sufficient doses including hallucinations, dissociation, and other psychotomimetic effects, dysphoria, anxiety, confusion, dizziness, disorientation, derealization, feelings of drunkenness, and bizarre, unusual, or disturbing dreams.
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Benzoylpas (more known as calcium benzoyl-PAS) is a benzoic acid-modified form of para-aminosalicylate, used to treat pulmonary tuberculosis.
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Status:
US Previously Marketed
First approved in 1956
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Status:
US Previously Marketed
Source:
MIOKIN by MALLINCKRODT
(1955)
Source URL:
First approved in 1955
Source:
MIOKIN by MALLINCKRODT
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Diprotrizoic acid is dipropionamino compound. It is a diagnostic aid. Diprotrizoic acid was introduced for urography but it produced more side effects than diatrizoic acid.
Status:
First approved in 1955
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
HYDROXYDIONE is a neuroactive steroid used formerly as a general anesthetic. It was discontinued due to a high incidence of post-anesthetic thrombophlebitis, delayed onset of anesthesia and an unacceptably long duration of action.
Status:
US Previously Marketed
Source:
Marsilid Phosphate by Hoffmann-La Roche
(1955)
Source URL:
First approved in 1955
Source:
Marsilid Phosphate by Hoffmann-La Roche
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy. Iproniazid is no longer clinically prescribed and has been withdrawn due to incidences of hepatotoxicity.
Status:
US Previously Marketed
First approved in 1955
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Pentoxyverine is a non-opioid antitussive used to prevent cough caused by common cold. It is used as an active ingredient of several oral over-the-counter cough suppressants alone or in combination with other medications, especially decongestants. Certuss is a combination of pentoxyverine and guaifenesin. Pentoxyverine is FDA pregnancy category C drug. Known as anticonvulsant, and spasmolytic agent.
Status:
US Previously Marketed
First approved in 1955
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Pentoxyverine is a non-opioid antitussive used to prevent cough caused by common cold. It is used as an active ingredient of several oral over-the-counter cough suppressants alone or in combination with other medications, especially decongestants. Certuss is a combination of pentoxyverine and guaifenesin. Pentoxyverine is FDA pregnancy category C drug. Known as anticonvulsant, and spasmolytic agent.
Status:
US Previously Marketed
Source:
TERGEMIST SODIUM ETHASULFATE by ABBOTT
(1955)
Source URL:
First approved in 1955
Source:
TERGEMIST SODIUM ETHASULFATE by ABBOTT
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Sodium ethasulfate is a clear, colorless, viscous, and nonflammable liquid that belongs to the sodium sulfate chemical group. Sodium ethasulfate is usually stable; however, it is incompatible with strong oxidizing agents. Due to its unique solubility and penetrating action, it is widely used in various end-user industries such as textile, chemical production, pharmaceuticals, agrochemicals, metal working, and food processing. Sodium ethasulfate is used as wetting agent in the textile industry. The product is used along with calcium hypochlorite as a bleaching agent. The product is used as mercerizing agent for cotton processing in the chemical industry. Sodium ethasulfate is employed as intermediate in anoinic surfactants that are used for dishwashing detergents. It is also used as surfactant in lye washing and peeling process. In the pharmaceutical industry, it is used to enhance the bactericidal properties of generic antiseptics that are more acidic. It is also employed as surfactant in penicillin production for breaking undesired reaction conditions.
